![]() | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||
|
Hello, fellow wikipedian David_Gerard. Can you please elaborate why you reverted my in Insilico Medicine? 😏 You claimed it was a “spam”, though it has nothing to do with WP:SPAM, so it sounded quite discriminatory and looks like poor behavior.-- Birulik ( talk) 21:11, 21 March 2020 (UTC)
Guidelines for paid editing are to propose changes to the article here at Talk, so that editors not affiliated with Insilico can either accept and implement or deny those changes. David notMD ( talk) 11:43, 4 April 2020 (UTC)
@ Robert McClenon:, @ David notMD: thank you for advice at WP:DRN and the Teahouse. I took it into account and reworked the text. I uploaded the new draft to my userspace, and going to suggest the edits here on the talk page. I will appreciate it if you’ll take a look. I tried to approach the text like it was written by someone else. I shortened it and removed the sources that may be considered not so reliable.
At first, I want to suggest edits to the History and the Recognition sections of the article. Here’s the text:
Insilico Medicine is a biotechnology company headquartered in Hong Kong. It applies deep learning, generative adversarial networks and reinforcement learning for biomarker development, clinical trials analysis, in silico drug discovery and other fields of digital medicine.
History
Insilico Medicine was founded by computer scientist and biotechnologist Alex Zhavoronkov in 2014. Zhavoronkov's studies in John Hopkins University and Moscow State University were focused on applying machine learning to biological research and Insilico was started up as a company that used deep neural networks to mine biological data to find potential drug targets. Later Zhavoronkov applied Ian Goodfellow's works on machine learning employing generative adversarial networks (GANs) and AI imagination to devise molecules with desired properties de novo instead of screening databases of chemical compounds. Insilico published its first peer-reviewed article in this field in 2016. Following that research the company developed a drug discovery engine based on generative tensorial reinforcement learning (GENTRL). Since its establishment the company has raised over $50 million from venture funds and longevity-focused investors such as British philanthropist and entrepreneur Jim Mellon. Its largest $37 million Series B investment round in September 2019 was led by Qiming Venture Partners joined by Eight Roads Ventures, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital Partners, Juvenescence and other companies.Recognition
Insilico's AI-based approach has brough it industry recognition. It was called "the most promising company" at Palo Alto Personalized Medicine World Conference in 2015. In 2018 Insilico was granted the Frost & Sullivan North American Technology Innovation Award for advances in aging research and drug development. In 2020 the company was also included in Fierce Biotech's list of top biotechnological companies and was listed one of the key in the field of generative molecule design in MIT Technology Review list of breakthrough technologies.
What’s gone:
What’s left:
What do you think, can I publish this? -- Birulik ( talk) 11:37, 22 April 2020 (UTC)
Article as it exists on 19 April 2021 is still highly promotional in tone and content. Naming a list investment companies does not contribute to notability. David notMD ( talk) 12:30, 19 April 2021 (UTC)
I'm not sure what exactly was the deflowering referred to by @ BD2412 justifying the removal of the advert tag since it had been added by @ MrOllie, see diff. AncientWalrus ( talk) 21:55, 2 October 2023 (UTC)
![]() | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||
|
Hello, fellow wikipedian David_Gerard. Can you please elaborate why you reverted my in Insilico Medicine? 😏 You claimed it was a “spam”, though it has nothing to do with WP:SPAM, so it sounded quite discriminatory and looks like poor behavior.-- Birulik ( talk) 21:11, 21 March 2020 (UTC)
Guidelines for paid editing are to propose changes to the article here at Talk, so that editors not affiliated with Insilico can either accept and implement or deny those changes. David notMD ( talk) 11:43, 4 April 2020 (UTC)
@ Robert McClenon:, @ David notMD: thank you for advice at WP:DRN and the Teahouse. I took it into account and reworked the text. I uploaded the new draft to my userspace, and going to suggest the edits here on the talk page. I will appreciate it if you’ll take a look. I tried to approach the text like it was written by someone else. I shortened it and removed the sources that may be considered not so reliable.
At first, I want to suggest edits to the History and the Recognition sections of the article. Here’s the text:
Insilico Medicine is a biotechnology company headquartered in Hong Kong. It applies deep learning, generative adversarial networks and reinforcement learning for biomarker development, clinical trials analysis, in silico drug discovery and other fields of digital medicine.
History
Insilico Medicine was founded by computer scientist and biotechnologist Alex Zhavoronkov in 2014. Zhavoronkov's studies in John Hopkins University and Moscow State University were focused on applying machine learning to biological research and Insilico was started up as a company that used deep neural networks to mine biological data to find potential drug targets. Later Zhavoronkov applied Ian Goodfellow's works on machine learning employing generative adversarial networks (GANs) and AI imagination to devise molecules with desired properties de novo instead of screening databases of chemical compounds. Insilico published its first peer-reviewed article in this field in 2016. Following that research the company developed a drug discovery engine based on generative tensorial reinforcement learning (GENTRL). Since its establishment the company has raised over $50 million from venture funds and longevity-focused investors such as British philanthropist and entrepreneur Jim Mellon. Its largest $37 million Series B investment round in September 2019 was led by Qiming Venture Partners joined by Eight Roads Ventures, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital Partners, Juvenescence and other companies.Recognition
Insilico's AI-based approach has brough it industry recognition. It was called "the most promising company" at Palo Alto Personalized Medicine World Conference in 2015. In 2018 Insilico was granted the Frost & Sullivan North American Technology Innovation Award for advances in aging research and drug development. In 2020 the company was also included in Fierce Biotech's list of top biotechnological companies and was listed one of the key in the field of generative molecule design in MIT Technology Review list of breakthrough technologies.
What’s gone:
What’s left:
What do you think, can I publish this? -- Birulik ( talk) 11:37, 22 April 2020 (UTC)
Article as it exists on 19 April 2021 is still highly promotional in tone and content. Naming a list investment companies does not contribute to notability. David notMD ( talk) 12:30, 19 April 2021 (UTC)
I'm not sure what exactly was the deflowering referred to by @ BD2412 justifying the removal of the advert tag since it had been added by @ MrOllie, see diff. AncientWalrus ( talk) 21:55, 2 October 2023 (UTC)